Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00003584 2016-05-12

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Phase 2 Completed

35 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00151086 2015-01-22

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Phase 1/2 Completed

33 enrolled

Genitourinary

Prostatic Neoplasms

NCT00002949 2013-09-05

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Phase 1 Completed

33 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT00627354 2011-05-16

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

90 enrolled

Genitourinary

Prostatic Neoplasms

NCT00006114 2011-03-01

Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Unknown

Genitourinary

Prostatic Neoplasms

NCT00278070 2008-02-29

Metronomic Oral Vinorelbine in Patients With Metastatic Tumors

Phase 2 Completed

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Clinical Trials

SMMART Adaptive Clinical Treatment (ACT) Trial

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Metronomic Oral Vinorelbine in Patients With Metastatic Tumors